Jyothirmayi G N, Modak R, Reddi A S
Department of Medicine, UMDNJ-New Jersey Medical School, Newark, NJ, USA.
Nephron. 2001 Feb;87(2):148-54. doi: 10.1159/000045904.
In this study, we examined the hypothesis whether exogenous administration of L-lysine in drinking water would reduce nonenzymatic glycation of glomerular basement membrane (GBM) collagen and thus albuminuria in streptozotocin-diabetic rats. The rationale is that the administered lysine would combine with the circulating glucose and make it unavailable to react with epsilon-amino groups of lysine of various proteins in these diabetic rats. Lysine (0.1%) was given to diabetic rats 7 days (early treatment) or 90 days (late treatment) after induction of hyperglycemia. The treatment was continued for 60 days. Diabetic rats had significantly higher glucose, glycosylated HbA(1), kidney weight, nonenzymatic glycation of GBM collagen, albuminuria, and systolic blood pressure than normal rats. Early treatment with lysine prevented the rise in glycosylated HbA(1) (normal 6.98 +/- 0.71% vs. diabetic - early treatment - 7.78 +/- 1.50%; p = NS), reduced glycosylation of GBM collagen by 86%, and significantly improved albuminuria. There was no significant effect on plasma glucose and systolic blood pressure. However, late treatment reduced the glycosylation of GBM collagen by 46% with a significant improvement in albuminuria. Plasma creatinine levels were not different between normal and untreated diabetic or lysine-treated diabetic rats; however, the creatinine clearance was significantly higher in all groups of diabetic rats (normal 0.45 +/- 0.09 vs. diabetic 2.02 +/- 0.39 ml/min; p < 0.001). The data suggest that early rather than late treatment is more beneficial in reducing nonenzymatic glycation of collagen, although both treatments significantly reduced albuminuria. There was no nephrotoxicity as assessed by plasma creatinine levels or creatinine clearances. These beneficial effects occurred independent of changes either in blood pressure or plasma insulin concentration.
在本研究中,我们检验了以下假设:饮用水中外源性给予L-赖氨酸是否会减少链脲佐菌素诱导的糖尿病大鼠肾小球基底膜(GBM)胶原蛋白的非酶糖基化,从而减少蛋白尿。其基本原理是,给予的赖氨酸会与循环中的葡萄糖结合,使其无法与这些糖尿病大鼠各种蛋白质中赖氨酸的ε-氨基发生反应。在诱导高血糖7天(早期治疗)或90天(晚期治疗)后,给糖尿病大鼠给予赖氨酸(0.1%)。治疗持续60天。糖尿病大鼠的血糖、糖化血红蛋白A1、肾脏重量、GBM胶原蛋白的非酶糖基化、蛋白尿和收缩压均显著高于正常大鼠。赖氨酸早期治疗可防止糖化血红蛋白A1升高(正常6.98±0.71% vs.糖尿病-早期治疗-7.78±1.50%;p=无显著性差异),使GBM胶原蛋白糖基化减少86%,并显著改善蛋白尿。对血糖和收缩压无显著影响。然而,晚期治疗使GBM胶原蛋白糖基化减少46%,蛋白尿显著改善。正常大鼠与未治疗的糖尿病大鼠或赖氨酸治疗的糖尿病大鼠之间的血浆肌酐水平无差异;然而,所有糖尿病大鼠组的肌酐清除率均显著更高(正常0.45±0.09 vs.糖尿病2.02±0.39 ml/min;p<0.001)。数据表明,早期治疗而非晚期治疗在减少胶原蛋白的非酶糖基化方面更有益,尽管两种治疗均显著减少了蛋白尿。根据血浆肌酐水平或肌酐清除率评估,未发现肾毒性。这些有益作用的发生与血压或血浆胰岛素浓度的变化无关。